Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge

Virology Journal

Volumn 10, Issue , 2013, Pages

  Eugene, Hermancia S ^a   Pierce Paul, Brooke R ^a   Cragio, Jodi K ^a,b   Ross, Ted M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 140; IMMUNOGLOBULIN G ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CLADISTICS; CONSENSUS SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; NONHUMAN; PURIFICATION; RHESUS MONKEY; VACCINATION; VIRUS ENVELOPE; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84875511162     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-102     Document Type: Article

References (48)

1. The origin and diversity of the HIV-1 pandemic. Hemelaar J, Trends Mol Med 2012 18 3 182 192 10.1016/j.molmed.2011.12.001 22240486
2. Diversity Considerations in HIV-1 Vaccine Selection. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Science (New York, NY) 2002 296 2354 2360 10.1126/science.1070441
3. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG, J Antimicrob Chemother 2003 51 2 229 240 10.1093/jac/dkg079 12562686
4. Viral sequence diversity: challenges for AIDS vaccine designs. McBurney SP, Ross TM, Expert Rev Vaccines 2008 7 9 1405 1417 10.1586/14760584.7.9.1405 18980542
5. Polyvalent AIDS Vaccines. Lu S, Grimes Serrano JM, Wang S, Curr HIV Res 2010 8 8 622 629 10.2174/157016210794088290 21054250
6. Computational Design of Centralized HIV-1 Genes. Arenas M, Posada D, Curr HIV Res 2010 8 8 613 621 10.2174/157016210794088263 21054255
7. Centralized HIV-1 Envelope Immunogens and Neutralizing Antibodies. Gao F, Liao H-X, Hahn BH, Letvin NL, Korber BT, Haynes BF, Curr HIV Res 2007 5 6 572 577 10.2174/157016207782418498 18045113
8. Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent clade B virus-like particle vaccine. McBurney SP LG, Forthal DN, Ross TM, AIDS Res Hum Retroviruses 2012 in Press
9. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA primeâ"protein boost HIV-1 vaccine in healthy human volunteers. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, Vaccine 2008 26 8 1098 1110 10.1016/j.vaccine.2007.12.024 18243434
10. Vaccination against Heterologous R5 Clade C SHIV: Prevention of Infection and Correlates of Protection. Lakhashe SK, Wang W, Siddappa NB, Hemashettar G, Polacino P, Hu SL, Villinger F, Else JG, Novembre FJ, Yoon JK, PLoS One 2011 6 7 22010 10.1371/journal.pone.0022010 21799765
11. Enhanced Cellular Immune Responses Elicited by an Engineered HIV-1 Subtype B Consensus-based Envelope DNA Vaccine. Yan J, Yoon H, Kumar S, Ramanathan MP, Corbitt N, Kutzler M, Dai A, Boyer JD, Weiner DB, Mol Ther 2007 15 2 411 421 10.1038/sj.mt.6300036 17235321
12. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. McBurney SP, Ross TM, Vaccine 2009 27 32 4337 4349 10.1016/j.vaccine.2009.04.032 19389453
13. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Santra S, Korber BT, Muldoon M, Barouch DH, Nabel GJ, Gao F, Hahn BH, Haynes BF, Letvin NL, PNAS 2008 105 30 10489 10494 10.1073/pnas.0803352105 18650391
14. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Liao H-X, Sutherland LL, Xia S-M, Brock ME, Scearce RM, Vanleeuwen S, Alam SM, McAdams M, Weaver EA, Camacho ZT, Virology 2006 353 2 268 282 10.1016/j.virol.2006.04.043 17039602
15. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies. Bower JF, Li Y, Wyatt R, Ross TM, Vaccine 2006 24 26 5442 5451 10.1016/j.vaccine.2006.03.063 16621193
16. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Pantophlet R, Wilson IA, Burton DR, PEDS 2004 17 10 749 758 15542540
17. An Anti-HIV-1 V3 Loop Antibody Fully Protects Cross-Clade and Elicits T-Cell Immunity in Macaques Mucosally Challenged with an R5 Clade C SHIV. Watkins JD, Siddappa NB, Lakhashe SK, Humbert M, Sholukh A, Hemashettar G, Wong YL, Yoon JK, Wang W, Novembre FJ, PLoS One 2011 6 3 18207 10.1371/journal.pone. 0018207 21483815
18. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD, Ferrai MG, Weiss DE, Letvin NL, Montefiori D, AIDS 2008 22 3 339 348 10.1097/QAD.0b013e3282f3ca57 18195560
19. Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 Adjuvant. Barnett SW, Burke B, Sun Y, Kan E, Legg H, Lian Y, Bost K, Zhou F, Goodsell A, zur Megede J, J Virol 2010 84 12 5975 5985 10.1128/JVI.02533-09 20392857
20. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Salazar-Gonzalez JF, Moldoveanu Z, Virology 2007 360 1 218 234 10.1016/j.virol.2006.10.017 17097711
21. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Weng Z, Weaver EA, Gao F, Virology 2006 352 2 438 449 10.1016/j.virol.2006.05.011 16780913
22. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Nature 2012 advance online publication
23. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines. Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB, Virology 2006 352 1 131 144 10.1016/j.virol.2006.04.030 21894641
24. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang Y, Depetris R, Marozsan AJ, Sanders RW, Proc Natl Acad Sci U S A 2011 108 11440 11445 10.1073/pnas.1101414108 21709254
25. Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design. Saphire EO, Parren PWHI, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA, Science 2001 293 5532 1155 1159 10.1126/science.1061692 11498595
26. Antibody-Mediated Fcψ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies. Holl V, Peressin M, Moog C, Viruses 2009 1 1265 1294 10.3390/v1031265 21994593
27. Antibodies, viruses and vaccines. Burton DR, Nat Rev Immunol 2002 2 9 706 713 10.1038/nri891 12209139
28. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, N Engl J Med 2012 366 14) 1275 86 22475592
29. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Nature advance online publication
30. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, N Eng J Med 2009 361 2209 2220 10.1056/NEJMoa0908492
31. Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, N Eng J Med 2012 366 14 1275 1286 10.1056/NEJMoa1113425
32. Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, J Virol 2009 84 1302 1313 19906907
33. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD, Ferrai MG, Weiss DE, Letvin NL, Montefiori D, AIDS 2008 22 3 339 348 10.1097/QAD.0b013e3282f3ca57 18195560
34. HIV Reservoirs and strategies for eradication. Smith M, Wightman F, Lewin S, Curr HIV/AIDS Rep 2012 9 5 15 10.1007/s11904-011-0108-2 22249405
35. Increased Loss of CCR5+ CD45RAâ' CD4+ T Cells in CD8+ Lymphocyte-Depleted Simian Immunodeficiency Virus-Infected Rhesus Monkeys. Veazey RS, Acierno PM, McEvers KJ, Baumeister SHC, Foster GJ, Rett MD, Newberg MH, Kuroda MJ, Williams K, Kim E-Y, J Virol 2008 82 5618 5630 10.1128/JVI.02748-07 18367534
36. Mamu-B*08-Positive Macaques Control Simian Immunodeficiency Virus Replication. Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, Soma T, Bean AT, Beal DR, Wilson NA, Rehrauer WM, J Virol 2007 81 8827 8832 10.1128/JVI.00895-07 17537848
37. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Lakhashe SK, Velu V, Siddappa NB, Dipasquale JM, Hemashettar G, Yoon JK, Rasmussen RA, Yang F, Lee SJ, Montefiori DC, Vaccine 2011 29 34 5611 24 10.1016/j.vaccine.2011.06.017 21693155
38. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. Sundling C, Forsell MN, O'Dell S, Feng Y, Chakrabarti B, Rao SS, Loré K, Mascola JR, Wyatt RT, Douagi I, J Exp Med 2010 207 9 2003 2017 10.1084/jem.20100025 20679401
39. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Leroux-Roels I, Koutsoukos M, Clement F, Steyaert S, Janssens M, Bourguignon P, Cohen K, Altfeld M, Vandepapelière P, Pedneault L, Vaccine 2010 28 43 7016 7024 10.1016/j.vaccine.2010.08.035 20728522
40. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E, Gagliardoni F, Fortini C, Cofano EB, Triulzi C, Cafaro A, Vaccine 2008 26 5 727 737 10.1016/j.vaccine.2007.11.040 18096278
41. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Ferrantelli F, Maggiorella MT, Schiavoni I, Sernicola L, Olivieri E, Farcomeni S, Pavone-Cossut MR, Moretti S, Belli R, Collacchi B, Vaccine 2011 29 16 2918 2932 10.1016/j.vaccine.2011.02.006 21338681
42. Immunodominant HIV-Specific CD8+ T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV Controllers. Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, Pollard RB, Yee HF, Martin JN, Deeks SG, Shacklett BL, J Virol 2010 84 19 10354 10365 10.1128/JVI.00803-10 20668079
43. HIV-Specific CD4 T Cell Responses to Different Viral Proteins Have Discordant Associations with Viral Load and Clinical Outcome. Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, Davis I, Lindqvist M, Pereyra F, Walker BD, Heckerman D, J Virol 2011 86 1 277 283 22031937
44. C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2. Toapanta FR, DeAlmeida DR, Dunn MD, Ross TM, Immunol Lett 2010 129 1 32 38 10.1016/j.imlet.2009.12.022 20064559
45. A Minimum CR2 Binding Domain of C3d Enhances Immunity Following Vaccination. Bower JF, Ross TM, Current Topics in Complement vol. 586 US: Springer, Lambris JD, 2006 249 264
46. Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle. Young KR, Smith JM, Ross TM, Virology 2004 327 2 262 272 10.1016/j.virol.2004.07.009 15351214
47. Kinetic Rates of Antibody Binding Correlate with Neutralization Sensitivity of Variant Simian Immunodeficiency Virus Strains. Steckbeck JD, Orlov I, Chow A, Grieser H, Miller K, Bruno J, Robinson JE, Montelaro RC, Cole KS, J Virol 2005 79 19 12311 12320 10.1128/JVI.79.19.12311-12320.2005 16160158
48. Chemoprophylaxis with Tenofovir Disoproxil Fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, Monsour M, Adams DR, Bashirian S, Johnson J, Soriano V, J Infect Dis 2006 194 7 904 911 10.1086/507306 16960777